Healthcare

EDMOND, Okla. – May 13, 2025 -- Watkins-Conti Products, Inc. ("Watkins-Conti"), a company that develops innovative solutions for women's pelvic health, today announced the peer-reviewed publication of clinical trial results evaluating Yōni.Fit® Bladder Support ("Yōni.Fit®"). Designed and manufactured in the United States, Yōni.Fit® obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2024 for the temporary management of urine leakage caused by stress urinary incontinence (SUI) in women, 18 years and older.

“Consideration of cutting off this life-saving resource to vulnerable youth and young adults goes against best practices in suicide prevention,” the letter continues. “We urge that you scrap this ill-advised plan. Our nation’s children deserve nothing less.” The 988 lifeline, funded by the Substance and Mental Health Services Administration, is a nationwide suicide and crisis hotline. In 2023, 988 began offering services tailored to LGBTQ+ youth to address rising mental health disparities and saw an average of 2,100 contacts per day. LGBTQ+ youth are four times more likely than their...

Shares of HCA Healthcare Inc. HCA rallied 1.33% to $368.10 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.72% to 5,886.55 and the Dow Jones Industrial Average DJIA falling 0.64% to 42,140.43.

This was the stock's second consecutive day of gains.

The U.S. Food and Drug Administration is taking action to remove ingestible fluoride prescription drugs for children off the market. In a press release, the FDA said products that are swallowed offer significant risk to infants and toddlers, unlike toothpaste with fluoride or fluoride rinses. The FDA also said the ingestion of fluoride products comes with risks like problems with the early development of the gut microbiome in childhood, thyroid disorders, weight gain, and decreased IQ. The federal agency provided links to several studies that point to worrying effects in...

OpenAI has been connecting with various companies in an effort to incorporate its generative artificial intelligence technology, and federal agencies are rumored to be part of that effort. While a contract with Open AI has yet to be confirmed, the Food and Drug Administration is suggesting that AI will be a part of its operations sooner rather than later. The announced an "aggressive timeline" to deploy artificial intelligence internally immediately, with full integration across all FDA centers by June 30, following the completion of a new generative AI pilot for...

Protesters opposing Republican cuts to Medicaid spending briefly shut down a House hearing on Tuesday. House Energy and Commerce Committee Chair Brett Guthrie (R-KY) kicked off the hearing by praising the GOP budget bill, saying it "unleashes American energy dominance, advances innovation, and protects access to care for our most vulnerable." "I have no doubt that we'll have some robust discussions today about these proposals," the chairman noted as a protest broke out in the committee room, shutting down the hearing. "No cuts to Medicaid! No cuts to Medicaid!" the...

WASHINGTON — U.S. health regulators announced plans Tuesday to phase out ingestible fluoride supplements sometimes used to strengthen children’s teeth, opening a new front in Health Secretary Robert F. Kennedy Jr.’s effort against a mainstay of dental care. The Food and Drug Administration said it will conduct a scientific review of the children’s products by late October with the aim of removing them from the market. It was not immediately clear whether the agency planned to formally ban the supplements or simply request that companies withdraw them. The products targeted...

The annual report “analyzes health care spending, quality, and equity performance, and includes updated recommendations to improve system oversight and affordability,“ officials said. The increasing demand was a key driver of an overall 7.8 percent increase in the state’s health care spending in 2023 – growth that exceeded the state’s own 6 percent cost growth target, according to the 2025 “Health Care Spending and Quality in Rhode Island” report, published Monday by the state Health Insurance Commissioner Cory King. PROVIDENCE – Spending on GLP-1s , the pricey drugs used to...